Dostarlimab: all 78 studies that test it
Page 1 of 1. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.
- Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingNCT07860450Phase 3
- A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerNot yet recruitingNCT07740720Phase 3
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingNCT07652515Phase 4
- A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT07408063Phase 2
- XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) PatientsNot yet recruitingNCT07381777Phase 2
- Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical CarcinomaRecruitingNCT07336147Phase 2
- pReOperative Dostarlimab and Novel Therapies in EndOmetrial CancerNot yet recruitingNCT07115927Phase 2
- A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)RecruitingNCT07108270Phase 2
- Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial CancerNot yet recruitingNCT07013851Phase 2
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)Not yet recruitingNCT06897527Phase 4
- Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon CancerRecruitingNCT06830239Phase 2
- A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)RecruitingNCT06796907Phase 1/2
- DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic CancerRecruitingNCT06757244Phase 2
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerRecruitingNCT06567782Phase 2
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIRecruitingNCT06333314Phase 2
- SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)RecruitingNCT06278857Phase 2
- A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaRecruitingNCT06256588Phase 3
- Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100RecruitingNCT06065462Phase 1/2
- DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II StudyRecruitingNCT06059495Phase 2
- A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)RecruitingNCT06023862Phase 2
- PREventing Second Cancers With DOSTARlimabRecruitingNCT05855811Phase 2
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerRecruitingNCT05855200Phase 3
- Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial CancerRecruitingNCT05819892Phase 1
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingNCT05700721Phase 2
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaRecruitingNCT05526989Phase 2
- Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon CancersRecruitingNCT05239546Phase 2
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingNCT05065021Phase 2
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingNCT03651206Phase 2/3
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMMTerminatedNCT06655818Phase 1/2Results posted
- Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2Results posted
- Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyActive, not recruitingNCT04655976Phase 2/3Results posted
- Niraparib + Dostarlimab In BRCA Mutated Breast CancerActive, not recruitingNCT04584255Phase 2Results posted
- Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)TerminatedNCT04581824Phase 2Results posted
- Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic CancerCompletedNCT04493060Phase 2Results posted
- Niraparib + Dostarlimab + RT in Pancreatic CancerCompletedNCT04409002Phase 2Results posted
- Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCCCompletedNCT04313504Phase 2Results posted
- Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in MelanomaActive, not recruitingNCT04139902Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerTerminatedNCT03955471Phase 2Results posted
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedNCT03739710Phase 2Results posted
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerActive, not recruitingNCT03602859Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian CancerCompletedNCT03574779Phase 2Results posted
- A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in ChinaActive, not recruitingNCT06640049Phase 2
- A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerActive, not recruitingNCT06521567Phase 1/2
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)Active, not recruitingNCT06472076Phase 3
- Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06405230Phase 1/2
- Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDerWithdrawnNCT06385548Phase 1/2
- Niraparib and Dostarlimab for Patients with MMR-D/MSI-H Colorectal CancersWithdrawnNCT06365970Phase 2
- A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerActive, not recruitingNCT06317311Phase 2
- Dostarlimab and Cobolimab in Advanced Cervical CancerActive, not recruitingNCT06238635Phase 2
- Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous CarcinomaActive, not recruitingNCT05870761Phase 2
- A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal CancerActive, not recruitingNCT05723562Phase 2
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerActive, not recruitingNCT05565378Phase 2
- Dostarlimab in Chemoresistant Gestational Trophoblastic NeoplasiaWithdrawnNCT05405192Phase 2
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
- Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First LineActive, not recruitingNCT05201547Phase 3
- Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPiWithdrawnNCT05126342Phase 2
- Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsActive, not recruitingNCT05060432Phase 1/2
- UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLCStatus unknownNCT04940637Phase 2
- A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal CancersTerminatedNCT04926324Phase 1
- Maintenance Niraparib and Dostarlimab in Advanced CholangiocarcinomaWithdrawnNCT04895046Phase 2
- Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerActive, not recruitingNCT04837209Phase 2
- Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and DostarlimabTerminatedNCT04779151Phase 2
- Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasActive, not recruitingNCT04701307Phase 2
- Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentStatus unknownNCT04679064Phase 3
- Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04673448Phase 1
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruitingNCT04446351Phase 1
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
- Study on TSR-042 in Advanced Clear Cell SarcomaTerminatedNCT04274023Phase 2
- Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix CancerActive, not recruitingNCT04068753Phase 2
- A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerActive, not recruitingNCT03981796Phase 3
- TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial CancerActive, not recruitingNCT03955978Phase 1
- TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiationActive, not recruitingNCT03833479Phase 2
- TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver CancerActive, not recruitingNCT03680508Phase 2
- Study of Niraparib and TSR-042 in Recurrent Endometrial CancerActive, not recruitingNCT03016338Phase 2
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsActive, not recruitingNCT02715284Phase 1